RBC Capital Markets reissued their outperform rating on shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a research note published on Friday. RBC Capital Markets currently has a $55.00 target price on the stock, up from their previous target price of $51.00.

A number of other equities analysts have also commented on the stock. Canaccord Genuity set a $50.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, September 14th. Brean Capital set a $48.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a report on Thursday, September 15th. Stifel Nicolaus boosted their price objective on shares of Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a buy rating in a report on Thursday, September 15th. Needham & Company LLC reissued a buy rating and issued a $52.00 target price (up previously from $45.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, September 15th. Finally, Cantor Fitzgerald boosted their target price on shares of Aerie Pharmaceuticals from $44.00 to $50.00 and gave the stock a buy rating in a research report on Thursday, September 15th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $49.40.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 38.85 on Friday. Aerie Pharmaceuticals has a 12 month low of $10.82 and a 12 month high of $39.01. The firm’s market cap is $1.08 billion. The company has a 50-day moving average of $21.55 and a 200-day moving average of $17.27.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. Equities analysts forecast that Aerie Pharmaceuticals will post ($2.77) EPS for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. acquired 250,000 shares of the stock in a transaction that occurred on Friday, July 22nd. The stock was acquired at an average price of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 8.77% of the company’s stock.

Several large investors have recently made changes to their positions in AERI. Barclays PLC increased its stake in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Aerie Pharmaceuticals by 3.0% in the second quarter. ProShare Advisors LLC now owns 22,695 shares of the company’s stock worth $399,000 after buying an additional 669 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock worth $744,000 after buying an additional 725 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock worth $1,961,000 after buying an additional 925 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Aerie Pharmaceuticals by 4.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,578 shares of the company’s stock worth $433,000 after buying an additional 1,019 shares in the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.